阿托伐他汀治疗高脂血症的疗效和安全性

被引:60
作者
柯元南
机构
[1] 北京阿托伐他汀临床试验协作组,中日友好医院心内科!北京
关键词
阿托伐他汀; 辛伐他汀; 高脂血症阿托伐他汀; 辛伐他汀; 高脂血症;
D O I
暂无
中图分类号
R589.2 [脂肪代谢障碍];
学科分类号
1002 ; 100201 ;
摘要
目的 评价阿托伐他汀 (北京红惠生物制药股份有限公司生产 ,商品名阿乐 )治疗高脂血症 ,特别是高胆固醇血症和混合型高脂血症的疗效和安全性。方法  2 11例高脂血症患者随机分为两组 :A组 :阿托伐他汀组 110例 (高胆固醇血症和混合型高脂血症分别为 5 8例和 5 2例 ) ,给予阿托伐他汀 10mg/d ;B组 :辛伐他汀组 10 1例 (高胆固醇血症和混合型高脂血症分别为 48例和 5 3例 ) ,给予辛伐他汀 10mg/d。 4周后如未达有效标准 ,均可加量至 2 0mg/d ,治疗 8周 ,观察降脂疗效和不良反应。结果 高胆固醇血症用阿托伐他汀治疗 ,总胆固醇 (TC)从 (6 .5 9± 0 .6 6 )mmol/L降至 (4 .6 2± 1.45 )mmol/L(下降 2 9.9% ) ;低密度脂蛋白胆固醇 (LDL C)从 (4 .0 2± 0 .77)mmol/L降至 (2 .44± 0 .6 4)mmol/L(下降 39.3% ) ;(TC -HDL C) /HDL C从 3.93± 1.2 2降至 2 .37± 1.5 4(下降 39.7% ) (P均 <0 .0 1)。阿托伐他汀降低LDL C ;(TC -HDL C) /HDL C作用优于同剂量的辛伐他汀 (P均 <0 .0 5 )。对于混合型高脂血症患者 ,阿托伐他汀可使甘油三酯 (TG)从 (3.17± 0 .97)mmol/L降低至 (2 .2 1± 1.0 3)mmol/L(P <0 .0 5 ) ,作用亦明显优于辛伐他汀 (P <0 .0 5 )。结论  (1)阿托伐他汀有明显的降低TC、LDL C、TG和 (TC -H
引用
收藏
页码:7 / 10
页数:4
相关论文
共 5 条
[1]  
Atorvastatin : a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Lea AP,McTavish D. Drugs . 1997
[2]  
A multicenter, double-blind,one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Dart A,Jerums G,Nicholson G,et al. The American Journal of Cardiology . 1997
[3]  
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Rebecca G,Bakker A,Davidson MH,et al. The Journal of The American Medical Association . 1996
[4]  
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Rebecca G,Bakker A,Davidson MH,et al. The Journal of The American Medical Association . 1996
[5]  
Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Cilla DD,Whitfield LR,Gibson DM,et al. Clinical Pharmacology and Therapeutics . 1996